リウマチ・膠原病治療薬ハンドブック

出版社： 文光堂
著者：
発行日： 2018-04-24
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784830620485
電子書籍版： 2018-04-24 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,160 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,160 円(税込)

購入する

商品紹介

リウマチ・膠原病の治療薬を概括し，その用法をまとめたガイドブック．本書では従来使用されている薬剤はもとより，2017年に販売承認されたベリムマブ，サリルマブなど最新の薬剤に至るまで解説している．本書は医師が臨床で用いやすいよう，薬剤ごとに(1)作用機序，(2)主な対象疾患と治療における位置づけ，(3)使用開始時の注意点，(4)使用方法（開始用量・用量変更），(5)使用禁忌薬・注意すべき併用薬，(6)副作用，(7)インフォームドコンセントのコツ，(8)主な適応疾患に対する効果（代表的な臨床データ），の構成で解説した．リウマチ・膠原病治療に携わる医師必携の1冊．

目次

  • I章．総論
    　1．リウマチ・膠原病治療総論
    　2．患者背景に応じた処方上の注意点
    　3．服薬・注射指導～抜糸時・周術期，妊娠希望時・妊婦・授乳，ワクチン接種時の注意点～

    II章．添付文書及びガイドラインに基づく薬剤と疾患の対応表

    III章．各論
    　Ａ．合成抗リウマチ薬(sDMARDs)
    　　1）従来型抗リウマチ薬(csDMARDs)
    　　　1．メトトレキサート
    　　　2．サラゾスルファピリジン
    　　　3．ブシラミン
    　　　4．イグラチモド
    　　　5．レフルノミド
    　　2）分子標的型抗リウマチ薬(tsDMARDs)
    　　　1．トファシチニブ
    　　　2．バリシチニブ
    　Ｂ．生物学的製剤
    　　1）TNF 阻害薬
    　　　1．インフリキシマブ
    　　　2．エタネルセプト
    　　　3．アダリムマブ
    　　　4．ゴリムマブ
    　　　5．セルトリズマブ ペゴル
    　　2）IL-6阻害薬
    　　　1．トシリズマブ
    　　　2．サリルマブ
    　　3）T細胞選択的共刺激調節剤
    　　　1．アバタセプト
    　　4）抗CD20抗体
    　　　1．リツキシマブ
    　　5）抗BLyS抗体
    　　　1．ベリムマブ
    　　6）抗RANKL抗体
    　　　1．デノスマブ
    　Ｃ．免疫抑制薬
    　　1）アルキル化剤
    　　　1．シクロホスファミド
    　　2）抗生物質
    　　　1．シクロスポリン
    　　　2．タクロリムス
    　　3）代謝拮抗薬
    　　　1．アザチオプリン
    　　　2．ミコフェノール酸モフェチル
    　　　3．ミゾリビン
    　Ｄ．ヒドロキシクロロキン
    　Ｅ．グルココルチコイド
    　Ｆ．非ステロイド性抗炎症薬
    　Ｇ．小児リウマチ性疾患における薬剤

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章. 総論

P.11 掲載の参考文献
1) Lucia Silva-Fernandez, et al : The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab : results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology, 55 : 2033-2039, 2016
PubMed
2) 一般社団法人日本リウマチ学会 調査研究委員会 生物学的製剤使用ガイドライン策定小委員会 : 関節リウマチ (RA) に対するTNF阻害薬使用ガイドライン, 改訂第8版, 2017
 
3) Singh JA, et al : 2015 American college of rheumatology guideline for the treatmet of rheumatoid arthritis. Arthritis Rheumatol, 68 : 1-26, 2016
 
4) 西村正治 : 非結核性抗酸菌症. 生物学的製剤と呼吸器疾患の診療の手引き, 克誠堂, 59-70, 2014
 
P.15 掲載の参考文献
1) 日本リウマチ学会MTX診療ガイドライン策定小委員会編 : 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン, 2016年改訂版【簡易版】, https://www.ryumachi-jp.com/publication/pdf/MTX2016kanni.pdf
 
2) 日本リウマチ学会, 調査研究委員会, 生物学的製剤使用ガイドライン策定小委員会編 : 関節リウマチ (RA) に対するTNF阻害薬使用ガイドライン, 2017改訂版. http://www.ryumachi-jp.com/info/guideline_TNF.html
 
3) 日本産婦人科学会編 : 産婦人科診療ガイドライン-産科編, 杏林社, 2017
 
4) Krause ML, et al : Management of rheumatoid arthritis during pregnancy : challenges and solutions. Open Access Rheumatol, 8 : 23-36, 2016
PubMed
5) Soh MC, et al : High-risk pregnancy and the rheumatologist. Rheumatology (Oxford), 54 : 572-587, 2015
PubMed
6) Kaneko K, et al : Tocilizumab and pregnancy : Four cases of pregnancy in young women with rheumatoid arthritis refractory to anti-TNF biologics with exposure to tocilizumab. Mod Rheumatol, 26 : 672-675, 2016
PubMed
7) Kubota T, et al : Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol, 17 : 531-533, 2007
PubMed

III章. 各論

P.29 掲載の参考文献
1) Smolen JS, et al : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2016 update. Ann Rheum Dis, 76 : 960-977, 2017
PubMed
2) 日本リウマチ学会MTX診療ガイドライン策定小委員会編 : 関節リウマチ治療におけるメトトレキサート (MTX) 診療ガイドライン2016年改訂版, 羊土社, 2016
 
3) 日本リウマチ学会編 : 関節リウマチ診療ガイドライン 2014, メディカルレビュー社, 2014
 
4) Harigai M : Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate : A review of the literature and current perspective. Mod Rheumatol, 28 : 1-8, 2018
PubMed
5) Lopez-Olivo MA, et al : Methotorexate for treating rheumatoid arthritis. Cochrane Database Syst Rev, 10 : CD000957, 2014
 
6) Atsumi T, et al : The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis, 75 : 75-83, 2016
PubMed
P.35 掲載の参考文献
1) Wada T, et al : Functional role of CD44v-xxCT system in the development of spasmolytic polypeptide-expressing metaplasia. Cancer Sci, 104 : 1323-1329, 2013
PubMed
2) 関節リウマチ診療ガイドライン 2014, 一般社団法人日本リウマチ学会
 
3) 医薬品インタビューフォーム, アザルフィジンEN錠. 2015年8月 (改訂第10版)
 
4) Dougados M, et al : Combination therapy in early rheumatoid arthritis : a randomized, controlled double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis, 58 : 20 225, 1999
 
5) Smolen J, et al : Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis : a double-blind, randomized, multicenter trial. Lancet, 353 : 259-266, 1999
PubMed
6) van der Heijde DM, et al : Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet, 1 (8646) : 1036-1038, 1989
PubMed
P.48 掲載の参考文献
1) 田中啓一ほか : 低分子抗リウマチ薬イグラチモド (コルベット(R) /ケアラム(R) 錠25mg) の薬理学的特性および臨床試験成績. 日薬理誌, 140 : 285-292, 2012
Medical*Online
2) 山本哲也ほか : 抗リウマチ薬Iguratimod (T-614) の免疫薬理学的検討B リンパ球のIg産生と細胞増殖に対する作用. 薬理と治療, 35 : 561-569, 2007
 
3) Hara M, et al : Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis : a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol, 17 : 1-9, 2007
 
4) Hara M, et al : Long-term safety study of iguratimod in patients with rheumatoid arthritis. Mod Rheumatol, 17 : 10-16, 2007
PubMed
5) Ishiguro N, et al : Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate : a randomized, double-blind, placebo-controlled trial. Mod Rheumatol, 23 : 430-439, 2013
PubMed
P.54 掲載の参考文献
1) Behrens F, et al : Update 2011 : leflunomide in rheumatoid arthritis-strengths and weaknesses. Curr Opin Rheumatol, 23 : 282-287, 2011
PubMed
2) Smith KJ, et al : Leflunomide : an immunemodulating drug that may have a role in controlling secondary infections with review of its mechanisms of action. J Drugs Dermatol, 14 : 230-236, 2015
 
3) Bilger A, et al : Leflunomide/ teriflunomide inhibit Epstein-Barrvirus (EBV) -induced lymphoproliferative disease and lytic viral replication. Oncotarget, 8 : 44266-44280, 2017
 
4) Sawada T, et al : Leflunomide-induced interstitial lung disease : prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford), 48 : 1069-1072, 2009
PubMed
5) Alfaro-Lara R, et al : Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin, (in press) http://dx.doi.org/10.1016/j.reuma.2017.07.020, 2017
 
P.60 掲載の参考文献
1) O'Shea JJ, et al : The JAK-STAT pathway : impact on human disease and therapeutic intervention. Annu Rev Med, 66 : 311-328, 2015
PubMed
2) van Vollenhoven, RF, et al : Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med, 367 : 508-519, 2012
 
3) Fleischmann R, et al : Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med, 367 : 495-507, 2012
PubMed
4) Burmester GR, et al : Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors : a randomised phase 3 trial. Lancet, 381 : 451-460, 2013
PubMed
5) Winthrop KL, et al : Herpes zoster and tofacitinib : clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol, 69 : 1960-1968, 2017
PubMed
6) Fleischmann R, et al : Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy) : a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet, 390 : 457-468, 2017
 
P.74 掲載の参考文献
1) Tracy D, et al : Tumor necrosis factor antagonist mechanisms of action : a comprehensive review. Pharmacol Ther, 117 : 244-279, 2008
 
2) Takeuchi T, et al : Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis, 67 : 189-194, 2008
PubMed
3) St Clair EW, et al : Combination of infliximab and methotrexate therapy for early rheumatoid arthritis : a randomized, controlled trial. Arthritis Rheum, 50 : 3432-3443, 2004
PubMed
4) Takeuchi T, et al : Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis : results from the RISING study. Mod Rheumatol, 19 : 478-487, 2009
 
5) Tanaka Y, et al : Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. Ann Rheum Dis, 69 : 1286-1291, 2010
PubMed
P.91 掲載の参考文献
1) Hu JS, et al : Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem, 288 : 27059-27067, 2013
 
2) Koike T, et al : Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients : postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol, 22 : 498-508, 2012
PubMed
3) B型肝炎治療ガイドライン (第3版), 日本肝臓学会 肝炎診療ガイドライン作成委員会編, https://www.jsh.or.jp/files/uploads/HBV_GL_ver3__Sep13.pdf
 
4) Breedveld FC, et al : A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum, 54 : 26-37, 2006
 
5) Keystone EC, et al : Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis : 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. J Rheumatol, 41 : 5-14, 2014
PubMed
6) Jaffe GJ, et al : Adalimumab in patients with active noninfectious uveitis. N Engl J Med, 375 : 932-943, 2016
PubMed
P.99 掲載の参考文献
1) 藤井秀二 : ゴリムマブ (シンポニー(R)) の薬理学的特徴および臨床試験成績. 日薬理誌, 141 : 275-285, 2013
Medical*Online
2) 若林宏 : リウマチ性疾患における分子標的治療. 岡山医会誌, 126 : 227-230, 2014
 
3) Frampton JE : Golimumab : a review in inflammatory arthritis. BioDrugs, 31 : 263-274, 2017
PubMed
4) Emery P, et al : Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis : twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum, 60 : 2272-2283, 2009
PubMed
5) Emery P, et al : Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis : five-year results of a randomized clinical trial. Arthritis Care Res, 68 : 744-752, 2016
PubMed
6) Tanaka Y, et al : GO-FORTH Study Group. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis : results of the GO-FORTH study. Ann Rheum Dis, 71 : 817-824, 2012
 
7) Takeuchi T, et al : Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs : results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks.Ann Rheum Dis, 72 : 1488-1489, 2013
PubMed
P.115 掲載の参考文献
1) Schaper F, et al : Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev, 26 : 475-487, 2015
PubMed
2) Ogawa J, et al : Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis, 65 : 1667-1669, 2006
 
3) Kobayashi I, et al : Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases. Mod Rheumatol, 25 : 335-343, 2015
PubMed
4) Koike T, et al : Effectiveness and safety of tocilizumab : postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol, 41 : 15-23, 2014
PubMed
5) Nishimoto N, et al : Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) : evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis, 66 : 1162-1167, 2007
 
6) Nishimoto N, et al : Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy eval uation of 24-week treatment with tocilizumab : subanalysis of the SATORI study. Mod Rheumatol, 20 : 539-547, 2010
 
7) Jones G, et al : Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis : the AMBITION study. Ann Rheum Dis, 69 : 88-96, 2010
PubMed
8) Gabay C, et al : Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA) : a randomised, double-blind, controlled phase 4 trial. Lancet, 381 : 1541-1550, 2013
PubMed
9) Dougados M, et al : Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders : 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis, 72 : 43-50, 2013
 
10) Huizinga TW, et al : Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis, 74 : 35-43, 2015
PubMed
11) Kaneko Y, et al : Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate : 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis, 75 : 1917-1923, 2016
PubMed
12) Ogata A, et al : Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken), 66 : 344-354, 2014
PubMed
13) Ogata A, et al : Longterm safety and efficacy of subcutaneous tocilizumab monotherapy : Results from the 2-year open-label extension of the MUSASHI study. J Rheumatol, 42 : 799-809, 2015
PubMed
14) Ogata A, et al : A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week : Results of the 12-week double-blind period. Mod Rheumatol, 28 : 76-84, 2018
 
P.125 掲載の参考文献
1) Rafique A, et al : Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human IL-6 receptor (IL-6R) alpha. Ann Rheum Dis, 72 (suppl 3) : A797, 2014
 
2) ケブザラ(R) 添付文書, サノフィ株式会社, 旭化成ファーマ株式会社, 2017年12月改定 (第2版)
 
3) Genovese MC, et al : Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate : results of a phase III study. Arthritis Rheumatol, 67 : 1424-1437, 2015
PubMed
4) Fleischmann R, et al : Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol, 69 : 277-290, 2017
PubMed
5) Burmester GR, et al : Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH) : a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis, 76 : 840-847, 2017
 
P.131 掲載の参考文献
1) Westhovens R, et al : Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheum rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis, 68 : 1870-1877, 2009
PubMed
2) Smolen JS, et al : Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis : new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX) -naive patients with Early Erosive rheumatoid arthritis (AGREE). Arthritis Res Ther, 17 : 157-169, 2015
 
3) Schiff M, et al : Efficacy and safety of abatacept or infliximab vs placebo in ATTEST : a phase III, multi-centre, randomised, double-blind, placebo controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis, 67 : 1096-1103, 2008
 
4) Westhovens R, et al : Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis, 68 : 1870-1877, 2009
PubMed
5) Genovese MC, et al : Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New Engl J Med, 353 : 1114-1123, 2005
PubMed
6) Schiff M, et al : Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis : two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis, 73 : 86-94, 2014
PubMed
P.140 掲載の参考文献
1) Igarashi T, et al : Factors affecting toxicity, response and progression-freesurvival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab : a Japanese phase II study. Ann Oncol, 13 : 928-943, 2002
 
2) Igarashi T, et al : Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol, 73 : 213-221, 2001
PubMed
3) Tobinai K, et al : Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. Ann Oncol, 9 : 527-534, 1998
PubMed
4) Cohen SB, et al : Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum, 54 : 2793-2806, 2006
PubMed
5) Stone JH, et al : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med, 363 : 221-232, 2010
PubMed
6) Jones RB, et al : Rituximab versus cyclophosphamide in ANCA-associate d renal vasculitis. N Engl J Med, 363 : 211-220, 2010
 
7) Iijima K, et al : Rituximab for childhood-onset, complicated, frequently r elapsing nephrotic syndrome or steroid-dependent nephrotic syndrome : a multicenter, double-blind, radomised, placebo-controlled trial. Lancet, 384 : 1273-1281, 2014
 
8) Godeau B, et al : Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura : results of a prospective multicenter phase 2 study. Blood, 112 : 999-1004, 2008
PubMed
9) Miyakawa Y, et al : Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy. Int J Hematol, 102 : 654-661, 2015
PubMed
P.152 掲載の参考文献
1) Cummings SR, et al : Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 361 : 756-765, 2009
PubMed
2) Nakamura T, et al : Clinical Trials Express : fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis : denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab, 99 : 2599-2607, 2014
PubMed
3) Cohen SB, et al : Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis : a twelve-month, multicenter, randomized, double-blind, place bo-controlled, phase II clinical trial. Arthritis Rheum, 58 : 1299-1309, 2008
 
4) Takeuchi T, et al : Effect of denosumab on Japanese patients with rheumatoid arthritis : a dose-response study of AMG 162 (Denosumab) in patients with Rheumatold arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE) -a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis, 75 : 983-990, 2016
 
5) Takeuchi T, et al : Effects of denosumab, a subcutaneous RANKL inhibitor, on the progression of structural damage in Japanese patients with rheumatoid arthritis treated with cs DMARDs : Results from the 12-month double blind phase 3, DESIRABLE study. Ann Rheum Dis, 76 : 841, 2017
 
P.159 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業難治性血管炎に関する調査研究班 有村義宏ほか編 : ANCA関連血管炎診療ガイドライン 2017, 診断と治療社, 2017
 
2) Houssiau FA et al : Immunosuppressive therapy in lupus nephritis : the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum, 46 : 2121-2131, 2002
 
3) Ntatsaki E, et al : BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford), 53 : 2306-2309, 2014
PubMed
4) Faurschou M, et al : Malignancies in Wegener's granulomatosis : incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol, 35 : 100-105, 2008
 
P.169 掲載の参考文献
1) 一般社団法人日本リウマチ学会 : 関節リウマチ診療ガイドライン 2014, 137, 2014
 
2) Singh JA, et al : Treatments for lupus nephritis : a systematic review and network metaanalysis. J Rheumatol, 43 : 1801-1815, 2016
PubMed
3) Ge Y, et al : The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis : a systematic review. Clin Rheumatol, 34 : 2097-2103, 2015
PubMed
P.176 掲載の参考文献
1) Gotestam Skorpen C, et al : The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis, 75 : 795-810, 2016
PubMed
2) Jayne D, et al : A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med, 349 : 36-44, 2003
PubMed
3) Guillevin L, et al : Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med, 371 : 1771-1780, 2014
PubMed
4) Houssiau FA, et al : Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis : results from the MAINTAIN Nephritis Trial. Ann Rheum Dis, 69 : 2083-2089, 2010
PubMed
P.182 掲載の参考文献
1) Hahn BH, et al : American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken), 64 : 797-808, 2012
PubMed
2) Mok CC, et al : Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis, 16 : 625-636, 2013
PubMed
3) van Vollenhoven RF, et al : Treat-to-target in systemic lupus erythematosus : recommendations from an international task force. Ann Rheum Dis, 73 : 958-967, 2014
PubMed
4) Chan TM, et al : Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med, 343 : 1156-1162, 2000
 
5) Chan TM, et al : Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. Journal of the American Society of Nephrology : JASN, 16 : 1076-1084, 2005
PubMed
6) Ginzler EM, et al : Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med, 353 : 2219-2228, 2005
 
7) Appel GB, et al : Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol, 20 : 1103-1112, 2009
PubMed
8) Rathi M, et al : Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int, 89 : 235-242, 2016
PubMed
9) Mok CC, et al : Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis : a randomised controlled trial and long-term follow-up. Ann Rheum Dis, 75 : 30-36, 2016
PubMed
10) Houssiau FA, et al : Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis : results from the MAINTAIN Nephritis Trial. Ann Rheum Dis, 69 : 2083-2089, 2010
PubMed
11) Tamirou F, et al : The 10-year followup of nephritis trial comparing azathioprine and mycophenolate mofetil for longterm immunosuppression of lupus nephritis. Arthritis and Rheumatology, 66 : S426-S427, 2014
 
12) Dooley MA, et al : Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med, 365 : 1886-1895, 2011
PubMed
13) Sundel R, et al : Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis : evidence from a two-phase, prospective randomized trial. Lupus, 21 : 1433-1443, 2012
PubMed
P.188 掲載の参考文献
1) Rokutanda R, et al : Safety and efficacy of mizoribine in patients with connective tissue diseases other than rheumatoid arthritis. Rheumatol Int, 34 : 59-62, 2014
PubMed
2) 本間光夫ほか : ループス腎炎に対するミゾリビンの臨床評価 (I). 臨床医薬, 5 : 795-824, 1989
Medical*Online
3) 塩川優一ほか : 慢性関節リウマチに対するミゾリビンの二重盲検試験. 炎症, 11 : 375-396, 1991
Medical*Online
4) 柏崎禎夫ほか : 慢性関節リウマチに対するブレディニン(R) 錠の用量比較試験 : 炎症, 16 : 269-289, 1996
Medical*Online
5) Kasama T, et al : Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate. Mod Rheumatol, 19 : 395-400, 2009
 
6) Ohtsubo H, et al : An investigation of the correlation between blood concentration of mizoribine and its efficacy in treatment of rheumatoid arthritis based on indices of drug survival and improvement in DAS28-CRP. Mod Rheumatol, 22 : 837-843, 2012
PubMed
7) Feng X, et al : Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis. Chin Med J, 127 : 3218-3723, 2014
PubMed
8) Yagi N, et al : Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis : Safety and efficacy during a 3-year follow-up. SAGE Open Medicine, 2 : 2050312114533960, 2014
PubMed
9) Takeuchi T : Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis : 2-Year results. Mod Rheumatol, 28 : 85-94, 2018
 
P.196 掲載の参考文献
1) Wallace DJ, et al : New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol, 8 : 522-533, 2012
PubMed
2) Canadian Hydroxychloroquine Study Group : A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med, 324 : 150-154, 1991
 
3) Ruiz-Irastorza G, et al : Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus : a systematic review. Ann Rheum Dis, 69 : 20-28, 2010
PubMed
4) Hahn BH, et al : American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res, 64 : 797-808, 2012
PubMed
5) Bertsias GK, et al : Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis, 71 : 1771-1782, 2012
 
6) van Vollenhoven RF, et al : Treat-to-target in systemic lupus erythematosus : recommendations from an international task force. Ann Rheum Dis, 73 : 958-967, 2014
PubMed
7) Izmirly PM, et al : Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation, 126 : 76-82, 2012
PubMed
8) Marmor MF, et al : Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 123 : 1386-1394, 2016
PubMed
9) Groot N, et al : European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus : the SHARE initiative. Ann Rheum Dis, 76 : 1788-1796, 2017
PubMed
10) Andreoli L, et al : EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis, 76 : 476-485, 2017
PubMed
11) Marmor MF, et al : Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology, 118 : 415-422, 2011
PubMed
12) Melles RB, et al : The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmology, 132 : 1453-1460, 2014
PubMed
13) Melles RB, et al : Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology, 122 : 110-116, 2015
PubMed
14) Yokogawa N, et al : Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus : a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol, 69 : 791-799, 2017
PubMed
15) Levy RA, et al : Hydroxychloroquine (HCQ) in lupus pregnancy : double-blind and placebo-controlled study. Lupus, 10 : 401-404, 2001
PubMed
16) Fessler BJ, et al : Systemic lupus erythematosus in three ethnic groups : XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum, 52 : 1473-1480, 2005
PubMed
17) Pons-Estel GJ, et al : Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis : LXV, data from a multiethnic US cohort. Arthritis Rheum, 61 : 830-839, 2009
PubMed
18) Alarcon GS, et al : Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus : data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis, 66 : 1168-1172, 2007
 
19) Shinjo SK, et al : Antimalarial treatment may have a time-dependent effect on lupus survival : data from a multinational Latin American inception cohort. Arthritis Rheum, 62 : 855-862, 2010
PubMed
20) Ruiz-Irastorza G, et al : Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus, 15 : 577-583, 2006
PubMed
21) Ruiz-Irastorza G, et al : Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther, 11 : R109, 2009
PubMed
P.207 掲載の参考文献
1) Harper L, et al : Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis : long-term follow-up. Ann Rheum Dis, 71 : 955-960, 2012
PubMed
2) Stone JH, et al : Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med, 363 : 221-232, 2010
PubMed
3) Stone JH, et al : Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377 : 1494-1495, 2017
PubMed
4) Buckley L, et al : 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res, 69 : 1095-1110, 2017
PubMed
5) Whittier X, et al : Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am, 42 : 177-189, 2016
PubMed
P.214 掲載の参考文献
1) Sheiner PA, et al : Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506 transplantation, 57 : 1132-1133, 1994
PubMed
2) Pope JE, et al : A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med, 153 : 477-484, 1993
PubMed
3) Catella-Lawson F, et al : Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med, 345 : 1809-1817, 2001
PubMed
4) Dentali F, et al : Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial. Ann Pharmacother, 40 : 1241-1247, 2006
PubMed
5) Kovesi TA, et al : Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis. N Engl J Med, 338 : 65-66, 1998
PubMed
6) Emery P, et al : Celecoxib versus diclofenac in long-term management of rheumatoid arthritis : randomised double-blind comparison. Lancet, 354 : 2106-2111, 1999
PubMed
7) Nissen SE, et al : PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med, 375 : 2519-2529, 2016
 
8) Hirayama A, et al : Assessing the cardiovascular risk between celecoxib and nonselective nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis and osteoarthritis. Circ J, 78 : 194-205, 2014
PubMed
P.231 掲載の参考文献
1) Hara R, et al : A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan. Mod Rheumatol, 25 : 858-864, 2015
PubMed
2) Mori M, et al : Acquisition of expanded indications for intravenous cyclophosphamide in the management of childhood rheumatic disease in general. Mod Rheumatol, 21 : 449-457, 2011
PubMed
3) Mori M, et al : Methotrexate for the treatment of juvenile idiopathic arthritis (JIA) -Process to the approval of indication for JIA in Japan-. Mod Rheumatol, 19 : 1-11, 2009
 
4) Mori M, et al : Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD) -refractory polyarticular course juvenile idiopathic arthritis : experience from Japanese clinical trials. Mod Rheumatol, 21 : 572-578, 2011
PubMed
5) Mori M, et al : Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease : a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. Sci Rep 8 : 1994, 2018
PubMed
6) Imagawa T, et al : Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol, 31 : 1713-1721, 2012
PubMed
7) Yokota S, et al : Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis : a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet, 371 : 998-1006, 2008
PubMed
8) Imagawa T, et al : Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol, 22 : 109-115, 2012
PubMed

書評

最近チェックした商品履歴

Loading...